Studies investigating microRNAs as potential biomarkers for cancer, immune-related diseases, or cardiac pathogenic diseases, among others, have exponentially increased in the last years. In particular, altered expression of specific miRNAs correlates with the occurrence of several diseases, making these molecules potential molecular tools for non-invasive diagnosis, prognosis, and response to therapy. Nonetheless, microRNAs are not in clinical use yet, due to inconsistencies in the literature regarding the specific miRNAs identified as biomarkers for a specific disease, which in turn can be attributed to several reasons, including lack of assay standardization and reproducibility. Technological limitations in circulating microRNAs measurement have been, to date, the biggest challenge for using these molecules in clinical settings. In this review we will discuss pre-analytical, analytical, and post-analytical challenges to address the potential technical biases and patient-related parameters that can have an influence and should be improved to translate miRNA biomarkers to the clinical stage. Moreover, we will describe the currently available methods for circulating miRNA expression profiling and measurement, underlining their advantages and potential pitfalls.

Measurements methods for the development of microRNA-based tests for cancer diagnosis / Precazzini, F.; Detassis, S.; Imperatori, A. S.; Denti, M. A.; Campomenosi, P.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - ELETTRONICO. - 22:3(2021), pp. 117601-117628. [10.3390/ijms22031176]

Measurements methods for the development of microRNA-based tests for cancer diagnosis

Precazzini F.;Detassis S.;Denti M. A.;
2021-01-01

Abstract

Studies investigating microRNAs as potential biomarkers for cancer, immune-related diseases, or cardiac pathogenic diseases, among others, have exponentially increased in the last years. In particular, altered expression of specific miRNAs correlates with the occurrence of several diseases, making these molecules potential molecular tools for non-invasive diagnosis, prognosis, and response to therapy. Nonetheless, microRNAs are not in clinical use yet, due to inconsistencies in the literature regarding the specific miRNAs identified as biomarkers for a specific disease, which in turn can be attributed to several reasons, including lack of assay standardization and reproducibility. Technological limitations in circulating microRNAs measurement have been, to date, the biggest challenge for using these molecules in clinical settings. In this review we will discuss pre-analytical, analytical, and post-analytical challenges to address the potential technical biases and patient-related parameters that can have an influence and should be improved to translate miRNA biomarkers to the clinical stage. Moreover, we will describe the currently available methods for circulating miRNA expression profiling and measurement, underlining their advantages and potential pitfalls.
2021
3
Precazzini, F.; Detassis, S.; Imperatori, A. S.; Denti, M. A.; Campomenosi, P.
Measurements methods for the development of microRNA-based tests for cancer diagnosis / Precazzini, F.; Detassis, S.; Imperatori, A. S.; Denti, M. A.; Campomenosi, P.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - ELETTRONICO. - 22:3(2021), pp. 117601-117628. [10.3390/ijms22031176]
File in questo prodotto:
File Dimensione Formato  
Precazzini_2021.pdf

accesso aperto

Descrizione: Articolo
Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 686.65 kB
Formato Adobe PDF
686.65 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/291590
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 33
social impact